Clinical trials: Elderly Lymphoma Patients
Diffuse Large B Cell Lymphoma
Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL
A phase 2 trial of pre-phase treatment before R-CHOP chemotherapy in elderly patients with newly diagnosed DLBCL
- Trial name
- NCT03465527
- Testing
- PrednisoLONE 50 MG
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Kosin University Gospel Hospital
Elderly Lymphoma Patients
Exercise for Elderly Lymphoma Patients
This pilot study was designed in a real-life setting to establish the feasibility, the safety and the activity of a supervised and combined Exercise Training (ET) program in adult and elderly lymphoma patients undergoing…
- Trial name
- NCT04259593
- Testing
- exercise training
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Roma La Sapienza
Diffuse Large B Cell Lymphoma
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
This is a prospective, single-arm, phase II study, and the purpose of this study is to evaluate the efficacy and safety of Pola-R2 regimen in newly diagnosed elderly diffuse large B cell lymphoma classified into un-fit or frail…
- Trial name
- NCT06176729
- Testing
- Polatuzumab Vedotin, Rituximab, Lenalidomide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yan Zhang, MD
Acute Lymphoblastic Leukemia
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
The purpose of this study is to test the safety of a new combination of three oral drugs in Ph+ ALL. These drugs are dexamethasone, dasatinib, and ruxolitinib. All three drugs have been studied before in humans.
- Trial name
- NCT02494882
- Testing
- Ruxolitinib, Dasatinib, Dexamethasone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B-Cell Lymphoma
Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study
This is a multicenter, single-arm, prospective study evaluating the efficacy and safety of polatuzumab vedotin and rituximab combined with a reduced-dose regimen of cyclophosphamide, doxorubicin and prednisone (Pola-R-miniCHP) as…
- Trial name
- NCT07908888
- Testing
- Polatuzumab Vedotin, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 26 people
- Sponsor
- The First Hospital of Jilin University
Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease
A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.
- Conditions
- Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease, Early Stage Parkinson's Disease
- Trial name
- NCT07630545
- Testing
- MTX325
- Where
- 18 sites in Australia, France and 2 more
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Mission Therapeutics
Diffuse Large B-cell Lymphoma
Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over
This is Phase II prospective trial of addition of rituximab to reduced dose CHOP chemotherapy in DLBC L patients aged 65 years and over.
- Trial name
- NCT02792491
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
- Volunteers
- 57 people
- Sponsor
- Pusan National University Hospital
Lymphoma
Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00060385
- Testing
- CHOP regimen, EPOCH regimen, cyclophosphamide
- Where
- Belgium
- Volunteers
- 3 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Leukemia, Myelodysplastic Syndromes
DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
RATIONALE: Combinations of biological substances in DT388IL3 fusion protein may be able to carry cancer killing substances directly to the cancer cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasm
- Trial name
- NCT00397579
- Testing
- DT388IL3
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer, Prostate Cancer
A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer
The purpose of this study is to examine whether psychoeducation counseling for older cancer patients undergoing treatment is feasible and worthwhile.
- Conditions
- Breast Cancer, Prostate Cancer, Lung Cancer, Lymphoma Cancer
- Trial name
- NCT00984321
- Testing
- group intervention and questionnaires, individual phone intervention and questionnaires, expressive writing (arm will not be include in the randomization)
- Where
- 2 sites in United States
- Volunteers
- 107 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
This phase II trial studies how well pirtobrutinib works in treating elderly patients with chronic lymphocytic leukemia (CLL). Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib work by…
- Trial name
- NCT07685717
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jennifer Woyach
Non Previously Treated CD20+ Diffuse Large B-cell Lymphoma
Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years
This study is a multicentric, phase II, open-label, non-randomized trial evaluating the efficacy of O-miniCHOP in patients aged over 80 years with non previously treated CD20+ diffuse large B-cell lymphoma (age-adjusted IPI=0…
- Trial name
- NCT01195714
- Testing
- Ofatumumab
- Where
- 84 sites in Belgium, France
- Volunteers
- 120 people
- Sponsor
- The Lymphoma Academic Research Organisation
Diffuse Large B-Cell Lymphoma
Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy
Study phase: Phase II Investigational product, dosage, and route of administration: Ibritumomab tiuxetan ("Zevalin) is composed of a murine IgG1 monoclonal antibody (ibritumomab) covalently bound to the chelating agent tiuxetan.
- Trial name
- CHOP21+R-Z (NCT00850512)
- Testing
- CHOP21-R, Zevalin
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- University of Bologna
Adult Acute Lymphocytic Leukemia
Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia
The aim of this study is to test feasibility and efficacy of a dose reduced chemotherapy in elderly patients with newly diagnosed acute lymphoblastic leukemia.
- Trial name
- NCT00199095
- Testing
- Adriamycin, Cyclophosphamide, Cytarabine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Goethe University
Diffuse Large B Cell Lymphoma, Age Over 80 Years
Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years
About 40% of Diffuse large B cell lymphoma relapse or is refractory, age is a prognostic factor of DLBCL, as elderly patients are not capable to received standard treatment, the prognosis of elderly patients is poor especially…
- Trial name
- R2DLBCL80 (NCT04622579)
- Testing
- lenalidomide combined with rituximab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangdong Provincial People's Hospital
CD20+ Aggressive B-Cell Lymphoma
OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine
The purpose of this study is to improve the outcome of elderly patients with CD20-Aggressive B-Cell Lymphoma and to reduce the toxicity of standard used Immuno-Chemotherapy by using an optimised schedule of the monoclonal…
- Trial name
- OPTIMAL>60 (NCT01478542)
- Testing
- Conventional Vincristine, Liposomal Vincristine, Ricover-scheme rituximab
- Where
- 127 sites in Germany
- Volunteers
- 1,152 people
- Sponsor
- Universität des Saarlandes
Diffuse Large B-Cell Lymphoma (DLBCL)
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Efficacy and safety of chidamide in combination with the R-mini CHOP regimen, followed by chidamide plus CD20 monoclonal antibody as maintenance therapy, in elderly patients with newly diagnosed MYC/BCL2 double-expressor DLBCL.
- Trial name
- NCT07493148
- Testing
- Chidamide, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ou Bai, MD/PHD
Diffuse Large B-Cell Lymphoma
Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL
To evaluate the efficacy and safety of the Pro-Pola （Pomalidomide, rituximab, orelabrutinib and polatuzumab vedotin) regimen in elderly patients (aged ≥70 years) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT07072208
- Testing
- Induction therapy-Pro regimen, Consolidation therapy-Pro-pola regimen
- Where
- China
- Volunteers
- 43 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Primary Central Nervous System Lymphoma
Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma
Hypothesis Our hypothesis is that maintenance chemotherapy will prolong complete remission obtained after a standard induction chemotherapy with an acceptable toxicity in the elderly.
- Trial name
- BLOCAGE-01 (NCT02313389)
- Testing
- Rituximab, Methotrexate, Temozolomide
- Where
- France
- Volunteers
- 428 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lymphoma
Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different ways may kill more cancer cells.
- Trial name
- NCT00053768
- Testing
- filgrastim, EPOCH regimen, cyclophosphamide
- Where
- 175 sites in Germany, Switzerland
- Volunteers
- 392 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group